NYSE · TEVA
Teva Pharmaceutical Industries Limited
$41.47+$1.50 (+3.75%)
Teva Pharmaceutical Industries Limited’s quoted price sits in the upper half of its reported 52-week range, 1.31% below the high.
Loading market information…
NASDAQ · AMPH · USD
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Amphastar Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 8.77% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Amphastar Pharmaceuticals, Inc.’s forward annual dividend is $0.30 per share, paid annual. The forward yield is 1.11% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
BEHIND THE RESULTS
Amphastar Pharmaceuticals, Inc.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of $0.86. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Amphastar Pharmaceuticals, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:41 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 7, 2025 | $0.74+12.12% vs estimate | $170.53M-1.46% vs estimate |
|---|
| Q4 2024 | Feb 27, 2025 | $0.92-8.91% vs estimate | $186.52M-1.19% vs estimate |
|---|
| Q3 2024 | Nov 6, 2024 | $0.96-3.03% vs estimate | $188.82M-1.7% vs estimate |
|---|
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
THE ANALYST VIEW
12 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 3 contributors · Median target $21.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$41.47+$1.50 (+3.75%)
Teva Pharmaceutical Industries Limited’s quoted price sits in the upper half of its reported 52-week range, 1.31% below the high.
$19.20+$0.43 (+2.29%)
Viatris Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.16% below the high.
$14.11-$0.04 (-0.28%)
Dr. Reddy's Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 9.96% below the high.
$21.35+$0.21 (+0.99%)
Amneal Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.52% below the high.
$8.91+$1.99 (+28.76%)
Bausch Health Companies Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.44% below the high.
$53.67+$1.87 (+3.61%)
Eton Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 19.14% below the high.
$24.03+$0.80 (+3.44%)
Collegium Pharmaceutical, Inc.’s quoted price sits in the lower half of its reported 52-week range, 52.69% below the high.
$0.65+$0.03 (+4.84%)
China Pharma Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.61% below the high.
